ISG15 is secreted from monocytes in response to type I interferons and causes natural killer (NK) cell proliferation and an augmentation of non-MCH (major histocompatibility complex) restricted cytotoxicity. Synthesis is stimulated by IFN-alpha or IFN-beta or IFN-omega, but not IFN-gamma. ISG15 expression is also induced by overexpression of interferon regulatory factors that participate in transcriptional regulation of IFN genes, and by influenza B virus. ISG15 is secreted also by cell lines of monocyte, T-lymphocyte, B-lymphocyte, human fibroblasts, and epithelial origins. The induction of terminal differentiation in human melanoma cells is associated with alterations in ISG15 expression. Enhancement of NK cell proliferation, augmentation of non-major histocompatibility complex-restricted cytotoxicity, and induction of IFN-gamma from T cells identify ISG15 as a member of the cytokine cascade and suggest that it may be responsible for amplifying and directing some of the immunomodulatory effects of IFN-alpha or IFN-beta. ISG15 has has also been shown to function intracellularly as a ubiquitin homolog.

Target	ISG15
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Tested Applications	WB, IHC
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Immunogen	KLH-conjugated synthetic peptide between 31-61 amino acids from the N-terminal region of human ISG15.
Purification	Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Isotype	IgG
Conjugation	Unconjugated
Storage	Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
Swiss Prot	P05161
NCBI Accession	NP_005092.1
Buffer	PBS containing 0.09% sodium azide.
UNSPSC Code	12352203
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.